lamivudine HBV / Generic mfg. - LARVOL DELTA

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study (ASH 2025) - "All HBV-positive patients received prophylactic antiviral treatment, predominantly with lamivudine (>90%)...Axi-cel was the most frequently used CAR-T product (53.5%), followed by tisa-cel (32.8%), brexu-cel (12.6%), and liso-cel (1.2%)...The lower incidence of CRS and milder ICANS severity observed in HBV-positive patients may point to potential immunomodulatory effects exerted by OBI status and/or antiviral prophylaxis. Systematic HBV screening and appropriate antiviral prophylaxis remain essential to minimize the rare risk of viral reactivation."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis. (PubMed, Diagnostics (Basel)) - "The use of two antiviral drugs were considered: entecavir (ETV) and lamivudine (LAM)... ML-based prediction of decompensation using electronic health records may assist clinicians in decision making. Findings of this study also underline the impact of antiviral therapy as a key predictor for decompensation."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Exploratory analysis of lamivudine legacy and clonal selection of HBs truncation mutants in HBV-related hepatocellular carcinoma. (PubMed, Infect Agent Cancer) - "While high-barrier NAs like entecavir effectively suppress viral replication, they do not eliminate transcriptionally active HBV integrants...Nevertheless, the results highlight the relevance of antiviral treatment history in shaping HBV mutational profiles and raise the possibility that integrant-derived HBs truncation variants could serve as biomarkers for HCC risk stratification. Early detection of such variants may help refine surveillance strategies in virally suppressed patients and inform future therapeutic approaches."

Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain. (PubMed, Virol J) - "Our studies reveal that SABG exhibits an antiviral activity against HBV by directly binding to the antigenic loop of surface protein, thereby impeding its secretion, which provides pharmacological evidence for the potential use of SABG as a candidate for the alternative treatment of HBV infection."

Journal • Hepatitis B • Infectious Disease • Inflammation

Human Immunodeficiency Virus and Hepatitis B Virus Co-infection in Pregnancy: A Review. (PubMed, Curr HIV/AIDS Rep) - "Guidelines have been revised to reflect the most recent evidence published on the safety and efficacy of both dolutegravir and tenofovir alafenamide in pregnancy...Recent advances in our understanding of the safety profile and efficacy of tenofovir disoproxil/alafenamide and dolutegravir has resulted in these being recommended as first line antiretrovirals, alongside Lamivudine, for HIV/HBV co-infection in pregnancy in United Kingdom, European and the United States guidelines. Appropriate antiretroviral therapy in pregnancy, along with prompt treatment of the neonate, combine to ensure very low rates of perinatal transmission of both HIV and HBV."

Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Obstetrics

A RARE CASE OF GUILLAN-BARRE SYNDROME RESULTING FROM HEPATITIS B FLARE IN A CHRONIC CARRIER (UEGW 2025) - "Clinical Case Summary: Our patient was a 66yr Chinese man who was treated for active Chronic Hepatitis B from 2009 with Lamivudine, Adefovir and then switched to Tenofovir from 2020 with long term undetectable Hepatitis B viral load (HBV VL) and normal Liver function tests...Nerve Conduction study (NCS) reported acute inflammatory demyelinating polyneuropathy.EMG was unremarkable.A probable diagnosis of GBS was made.His ALT was down to 304 and HBV VL 3.82 log.NCS repeated 2 months later and showed similar inflammatory demyelinating polyneuropathy.NCS repeated 4 months later showed significant improvement which confirmed a diagnosis of GBS1 year from his first presentation, he recovered fully.Only 7 cases of Hepatitis B related GBS have been reported in the literature. Our case highlights GBS resulting from Hepatitis B flare"

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

EFFECT OF SWITCHING FROM PRIOR NUCLEOS(T)IDE ANALOGUE(S) TO TENOFOVIR ALAFENAMIDE ON LIPID PROFILE AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC HEPATITIS B (AASLD 2025) - "The prior NUCs were as follows: 47 Lamivudine (LAM), 2 Entecavir (ETV), and 41 TDF-based... Significant increase in LDL-c and total cholesterol after switching to TAF were observed only in patients with prior TDF, but not in those with prior ETV or LAM. Careful monitoring of lipids after the switch may not universally needed. Data regarding long-term cardiovascular outcomes are warrant."

Clinical • Cardiovascular • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Infectious Disease • Inflammation

SAFE BUT NOT SILENT: HBV REACTIVATION IN NON-LIVER ORGAN TRANSPLANTATION (AASLD 2025) - "Induction therapy mainly involved anti-thymocyte globulin (65.3%), while maintenance commonly included calcineurin inhibitors (97.4%), antimetabolites (94.8%), and prednisone (84.1%). HBV prophylaxis was given to 43% of patients, using tenofovir alafenamide (33.0%), lamivudine (29.3%), entecavir (27.8%), and tenofovir disoproxil fumarate (2.2%)... Although relatively uncommon, HBV reactivation in non-liver solid organ transplant recipients remains a clinically significant concern. These findings underscore the importance of thorough pre-transplant screening and individualized antiviral prevention strategies. Although the number of patients is limited, the data supports the cautious use of HBsAg-positive donors under strict prophylactic protocols, offering a potential avenue to expand the donor pool without compromising recipient safety."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Potential Occult Hepatitis B Infection in MS Patients Receiving Ofatumumab: Prevalence,Risk Stratification, and Implications for Lamivudine Prophylaxis (ECTRIMS 2025) - "The presence of antibodies to hepatitis B core antigen in the peripheral blood of MS patients reflects a risk of HBV reactivation in patients treated with Ofatumumab but not all pOBI patients require Lamivudine treatment and only about 10% of treated patients need infectious disease consultations after appropriate HBV screening. Therefore, the impact of liver screening is necessary to prevent HBV reactivation and to select, together with infectious disease specialists, a subgroup of patients who need lamivudine prophylaxis."

Clinical • CNS Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Multiple Sclerosis

Human Embryoid Body-Based Assays for Preclinical Screening of Potential Teratogenic Drugs: Antiviral Drugs for Hepatitis B Virus as Examples. (PubMed, Stem Cells Dev) - "Animal tests are not always reliable for accurately identifying human teratogens, as evidenced by the infamous thalidomide case...Additionally, we subjected our hEB systems to Cmax doses of four nucleoside/nucleotide analogs (adefovir dipivoxil [ADV], entecavir [ETV], lamivudine [LAM], and tenofovir disoproxil fumarate [TDF]), which are used for anti-hepatitis B virus treatment and belong to different pregnancy-related risk categories...TDF and ADV appear to be safer options during the very early stages of embryonic development compared with LAM and ETV. Our findings indicate that EB transcriptomics-based analyses can accurately identify potent teratogens and aid in assessing the potential risk of commonly prescribed drugs during pregnancy."

Journal • Preclinical • Hepatitis B • Infectious Disease • Inflammation

Investigation of hepatitis B virus mutations associated with immune escape and drug resistance in human immunodeficiency virus-infected patients. (PubMed, F1000Res) - "Mutations causing resistance to lamivudine and telbivudine were M204V, L180M, V163I, and S202K; with S202K also causing resistance to entecavir and adefovir resistance mutation were I253Y, I223V and M250I...Although there is no statistical significance amongst the mutations associated with drug resistance and vaccine escape. These mutations could have clinical implications that could have therapeutic repercussions by influencing the correct clinical diagnosis and treatment in HBV/ HIV co-infected individuals."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Cancer • Oncology • Solid Tumor

Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients. (PubMed, World J Hepatol) - "HBV rtCYE/rtCYEI mutations have a limited effect on TDF susceptibility and are not sufficient to cause TDF resistance."

Journal • Hepatitis B • Infectious Disease • Inflammation

Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis. (PubMed, Virol J) - "The top three keywords were “therapy” (489 occurrences, total link strength: 2045), “lamivudine” (409 occurrences, total link strength: 2013), and “combination” (243 occurrences, total link strength: 1249). Keywords burst analysis highlighted emerging trends, including “functional cure” (2021–2024), “hbsag loss” (2021–2024), “entecavir” (2019–2024), and “guidelines” (2017–2024)...not applicable. The online version contains supplementary material available at 10.1186/s12985-025-02922-4."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Analysis of HBV resistance mutations in treatment of chronic hepatitis B with entecavir and lamivudine (PubMed, Zhonghua Yu Fang Yi Xue Za Zhi) - "The median age and alanine aminotransferase levels of patients with drug resistance mutations in the two therapy groups were higher than those in the non-mutation group[(t=-4.743, P<0.001)/(Z=-4.809, P<0.001), (Z=-2.667, P=0.007)/(Z=-2.001, P=0.045)].Age(OR=1.044, 95%CI:1.023-1.066), compensated cirrhosis(OR=2.163, 95%CI:1.193-3.922), liver cancer(OR=4.017, 95%CI:2.170-7.436) and the treatment regimen(OR=6.075, 95%CI:3.889-9.489) were associated with drug resistance gene mutations(P<0.001).The mutation rates in different stages of chronic liver disease(CHB, cirrhosis, and liver cancer)showed statistically significant(χ2=41.038, P<0.001;χ2=15.894, P<0.001).The overall mutation rates of ETV-related genes in the two therapy groups were 25.49% and 32.39%, respectively.Additionally, 10 mutation sites and 38 variant combinations were identified, containing five common combinations being rtL180M, rtM204V, rtS202G;rtL180M, rtM204V, rtT184A; rtL180M, rtM204V,..."

Journal • Retrospective data • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor

Functional cure in a child with chronic hepatitis B with rtM204I mutation through an atypical serological response: a case report. (PubMed, Transl Pediatr) - "A 4-year-old boy infected with HBV through mother-to-child transmission experienced virological rebound (HBV DNA, 4.66×107 IU/mL) after 12 months of lamivudine (LAM) monotherapy...The treatment regimen was adjusted to tenofovir disoproxil fumarate (TDF) combined with pegylated interferon α-2a (PegIFNα-2a)...This case indicated that in children with rtM204I mutation, optimizing antiviral therapy combined with PegIFNα-2a can achieve a functional cure despite atypical serological response patterns. Long-acting interferons have significant therapeutic value in pediatric patients with drug-resistant mutations."

Journal • Hepatitis B • Infectious Disease • Inflammation • Pediatrics • IFNA1

Is long-acting injectable antiretroviral therapy safe in countries with high hepatitis B prevalence?: insights from the IMPALA study (IAS-HIV 2025) - P3 | "The WHO recommended first-line HIV regimen (tenofovir disoproxil, lamivudine, dolutegravir, TLD) both prevents and treats hepatitis B disease. Novel long-acting (LA) injectable antiretrovirals including cabotegravir (CAB) and rilpivirine (RPV), are not active against hepatitis B, raising concerns about reactivation in individuals with prior hepatitis B exposure... The high number of hepatitis B-related screen-outs highlights challenges for LA therapy in hepatitis B endemic countries. While hepatitis B reactivation did not occur in individuals with immunity (HepBsAb >10 IU), the risk of de novo infection remains in those receiving CAB+RPV LA without immunity. This demonstrates the need for strengthened vaccination efforts, particularly among those switching to CAB+RPV LA."

Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Entecavir Monotherapy for Chronic Hepatitis B After Liver Transplantation: A 17-Year Follow-Up Study (WTC 2025) - "Exclusion criteria: non-entecavir-based regimens, pre-LT lamivudine resistance, hepatitis C co-infection, re-transplantation, or HBV-positive grafts.Hepatitis B immunoglobulin (HBIG) and therapeutic vaccination were not utilized... Entecavir monotherapy achieved durable HBV control post-LT, with 94.9% HBsAg seroclearance at 15 years and 100% sustained HBV DNA suppression at 17 years. These results support antiviral monotherapy without HBIG as the standard prophylactic regimen for CHB patients post-LT."

Monotherapy • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Transplantation • AFP

High prevalence of Hepatitis B virus infection among people living with advanced HIV disease in Botswana (IAS-HIV 2025) - "The prevalence of HBV in people with AHD is high, highlighting the importance of HBV screening and HIV/HBV co-management in this population."

Metastases • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

HIV PrEP programmes as a framework for diagnosing and treating HBV infection in adolescents and young adults in KwaZulu-Natal, South Africa. (PubMed, J Virus Erad) - "Guidelines for Hepatitis B treatment released by the World Health Organization in 2024 include the potential for use of dual therapy, combining tenofovir with either emtricitabine or lamivudine...Sexual reproductive health and PrEP programmes provide an opportunity for HBV testing and treatment. However, attrition from the care cascade at each step highlights the pressing need for interventions that address barriers to sustainable delivery of long-term care."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

ROS confer resistance to 3 TC in p53 mutant colorectal cancer by promoting autophagy and ER stress. (PubMed, Eur J Pharmacol) - "Lamivudine (3 TC), a nucleoside reverse transcriptase inhibitor (NRTI) commonly used for treating Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV), has recently demonstrated anticancer activity against p53-mutant CRC in Phase 2 clinical trials...Furthermore, we observed that ROS induced by 3 TC stimulates autophagy independently of the protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway and also activates the activating transcription factor 4 (ATF4)-mediated endoplasmic reticulum (ER) stress pathway. By inhibiting autophagy and ER stress, the anticancer effect of 3 TC was enhanced. In summary, our findings demonstrate that ROS accumulation attenuates the anticancer efficacy of 3 TC by promoting autophagy and ER stress, providing novel insights into the molecular mechanisms underlying 3 TC's therapeutic role in p53-mutant CRC."

Journal • P53mut • Colorectal Cancer • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor • ATF4 • TCF4 • TP53

Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B. (PubMed, PLoS One) - "Significant increase in LDL-c and total cholesterol after switching to TAF were observed only in patients with prior TDF, but not in those with prior ETV or LAM. Careful monitoring of lipids after the switch may not be universally needed. Data regarding long-term cardiovascular outcomes are warrant."

Journal • Observational data • Cardiovascular • Hepatitis B • Hypertension • Infectious Disease • Inflammation

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

Expression variation of Akt and cytokines in lamivudine-resistant HBV rare mutation that prematurely truncates the overlapping surface protein. (PubMed, Hum Immunol) - "The current study reveals for the first time the underlying immunological processes that render detrimental effects to lamivudine-resistant rare mutations, in particular sW196*(Stop) of HBV that can be explained by downregulation of IFN-gamma, a known cytokine associated with efficient viral clearance, together with upregulation of IL-6 known to be associated with disease progression and HCC. Understanding the molecular and immunological mechanisms in such HBV mutations is furthered by the choreographed event of increased TNF-alpha expression, which is known to be linked to liver damage."

Journal • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Oncology • Solid Tumor • AKT1 • IFNG • IL6 • TNFA

EFFICACY AND SAFETY OF TREATMENTS FOR CHRONIC HEPATITIS D: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 19 RANDOMIZED CONTROLLED TRIALS (DDW 2025) - "Objective: This meta-analysis evaluates the efficacy and safety of pharmacological treatments for chronic HDV, including Lamivudine, Peg-IFN, Ribavirin, IFN alfa-2a, Adefovir, Bulevirtide, Lonafarnib, TDF, and Entecavir... Bulevirtide with Peg-IFN is the most effective and safest treatment for chronic HDV, particularly in cirrhotic patients. TDF shows potential but requires further study in larger, long-term trials. Adverse effects from therapies like Peg-IFN and Lonafarnib emphasize the need for careful monitoring."

Retrospective data • Review • Anemia • Fatigue • Gastrointestinal Disorder • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis • Pain